Seres Therapeutics reported a net income of $4.6 million for Q2 2026, driven by a $25 million gain from the Nestlé VOWST milestone termination payment. The company holds $15.6 million in cash and projects operations funded through Q1 2027. Clinical updates highlighted that 80% of SER-155 recipients achieved immunosuppressive-free response for irEC, prompting partner engagement. Seres also terminated its Sidney Street lease to reduce costs and recorded a $5.8 million impairment charge. The company operates in the biotechnology industry, developing live biotherapeutics.
